Sun Pharma
The pharmaceutical industry comes under Healthcare group. It’s a Non-commodity type industry.
Industry Strengths
Growing demand as lifestyles continue to become sedentary leading to particular disorders.
Inelastic demand for basic medicines for chronic illnesses.
Low R&D, trial and production costs especially for generics.
Access to foreign markets due to mergers and acquisitions and strategic tie-ups.
Industry Weakness
Uncertain government regulations on pricing
High competition from foreign companies
Dependence of regulators in developed markets
High risk of litigations and patents disputes especially in developed markets
Growth Drivers
Growing population with higher life expectancy and greater number of old people
Awareness of latest medicine technologies
Increasing lifestyle disorders such as diabetes, cardiac and obesity
Very strong demand for generics in developed and domestic markets due to its cheap pricing.
Growth in hospital and healthcare sector
Sun Pharmaceuticals (SUNP) is one of the fastest growing companies in India as well as globally. It has a highly impressive track record of organic and inorganic growth. Various US acquisitions augment SUNP’s pipeline with differentiated products, and SUNP has turned around business in a highly profitable manner – Taro/ TDPL/ Natco’s brands/ etc.
Segments and Products
The Company's business segments include
1.US Business,
2.Indian Branded Generics Business,
3.Emerging Markets,
4.Global Consumer Healthcare Business and
5.Active Pharmaceutical Ingredients (API).
Its Rest of World segment includes Western Europe, Canada, Australia, New Zealand and other markets. .
The Company offers its products to therapy areas, such as
1.cardiology,
2.neuro-psychiatry,
3.gastroenterology,
4.anti-infective,
5.diabetology and
6.dermatology.
The Company's products include AB PHYLLINE, ABZORB DUSTING POWDER, ACAMPROL, ACOSTIN 3 MIU, ACOSTIN FORTE and AB PHYLLINE SR 200.
They also produce intermediates in a range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.
Its manufacturing units are situated in India, the United States and Brazil, among others. Its units produce generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retroviral (ARVs) and APIs.
19.42
Sep'17
2.14
Sep'17
-58.17
Sep'17
-58.07
Sep'17
24.69
159.65
2.59
69.16
9.55
160.77
Fund | Sep-17 |
---|---|
ICICI Prudential Mutual Fund | 2.622 |
SBI Mutual Fund | 0.811 |
UTI Mutual Fund | 0.643 |
Reliance Mutual Fund | 0.539 |
HDFC Mutual Fund | 0.382 |
Axis Mutual Fund | 0.353 |
Kotak Mahindra Mutual Fund | 0.313 |
Franklin Templeton Mutual Fund | 0.270 |
DSP BlackRock Mutual Fund | 0.256 |
L&T Mutual Fund | 0.221 |
Address: Sun Pharma Advanced Research Centre (S P A R C), Tandalja, Vadodara, Gujarat - 390020 | Phone: 0265- 5515500 / 5515600 / 5515700 | Fax: 0265- 2354897
Email: secretarial@sunpharma.com
Website: www.sunpharma.com
Registrar & Transfer Agent: Link Intime India Pvt Ltd.
Address: C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra, C 101, 247 Park, LBS Marg, Vikhroli (West) | Phone: 91-022-49186000 | Fax: 91-022-49186060
Email: helpdesk@linkintime.co.in
Website: www.linkintime.co.in
2 Comments